NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2031240092

Registered date:17/05/2024

A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedAlzheimer's Disease
Date of first enrollment14/02/2024
Target sample size
Countries of recruitment
Study typeObservational
Intervention(s)

Outcome(s)

Primary Outcome1.Number of Participants With Amyloid Related Imaging Abnormality-Oedema/Effusion (ARIA-E) and Amyloid Related Imaging Abnormality-Microhemorrhage and Hemosiderin Deposit, and Cerebellar Microhaemorrhage (ARIA-H) 2.Number of Participants With Interruption or Discontinuation of Lecanemab After Onset of ARIA
Secondary OutcomeNumber of Participants With Infusion Related Reaction

Key inclusion & exclusion criteria

Age minimum>= 18age old
Age maximumNot applicable
GenderBoth
Include criteriaAll participants treated with Leqembi
Exclude criteriaNone

Related Information

Contact

Public contact
Name Inquiry Service
Address 6-10 KOISHIKAWA 4-CHOME BUNKYO-KU TOKYO Tokyo Japan 112-8088
Telephone +81-120-419-497
E-mail eisai-chiken_hotline@hhc.eisai.co.jp
Affiliation Eisai Co. Ltd.
Scientific contact
Name Inquiry Service
Address 6-10 KOISHIKAWA 4-CHOME BUNKYO-KU TOKYO Tokyo Japan 112-8088
Telephone +81-120-419-497
E-mail m-sakurai@hhc.eisai.co.jp
Affiliation Eisai Co. Ltd.